[go: up one dir, main page]

Trzaska et al. - Google Patents

The 2, 6-diaminopurine as a highly potent corrector of UGA nonsense mutations in cancers and other genetic diseases

Trzaska et al.

View PDF
Document ID
2126784079573225917
Author
Trzaska C
Amand S
Bailly C
Leroy C
Marchand V
Duvernois-Berthet E
Saliou J
Benhabiles H
Werkmeister E
Chassat T
Guilbert R
Hannebique D
Mouray A
Copin M
Moreau A
Reix10 P
Hubert11 D
Gérardin12 M
Adriaenssens13 E
Kulozik14 A
Westhof15 E
Tulasne D
Motorin16 Y
Rebuffat S
Lejeune F

External Links

Snippet

Nonsense mutations cause about ten percent of genetic disease cases, and no treatments are available for these patients. Nonsense mutations can be corrected by molecules with nonsense mutation readthrough activity. Recently, an extract of the mushroom Lepista …
Continue reading at core.ac.uk (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid

Similar Documents

Publication Publication Date Title
Trzaska et al. 2, 6-Diaminopurine as a highly potent corrector of UGA nonsense mutations
US10139394B2 (en) Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl tRNA synthetase
Loo et al. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism
Paytubi et al. ABC50 promotes translation initiation in mammalian cells
Huang et al. The nucleolar phosphoprotein B23 interacts with hepatitis delta antigens and modulates the hepatitis delta virus RNA replication
Verrills et al. Alterations in γ-actin and tubulin-targeted drug resistance in childhood leukemia
Verghese et al. Prostasin regulates epithelial monolayer function: cell-specific Gpld1-mediated secretion and functional role for GPI anchor
WO1997034611A1 (en) Novel cystic fibrosis treatment
Dobrzynski et al. Newly-synthesized β-tubulin demonstrates domain-specific interactions with the cytosolic chaperonin
Munkonge et al. Identification and functional characterization of cytoplasmic determinants of plasmid DNA nuclear import
Shi et al. The tRNA Gm18 methyltransferase TARBP1 promotes hepatocellular carcinoma progression via metabolic reprogramming of glutamine
EP1625853B1 (en) Apoptosis inducer for cancer cell
US7364870B2 (en) MK2 interacting proteins
Apuzzo et al. Cross-talk between the paired domain and the homeodomain of Pax3: DNA binding by each domain causes a structural change in the other domain, supporting interdependence for DNA Binding
Trzaska et al. The 2, 6-diaminopurine as a highly potent corrector of UGA nonsense mutations in cancers and other genetic diseases
Li et al. USP36 SUMOylates Las1L and Promotes Its Function in Pre–Ribosomal RNA ITS2 Processing
US7879563B2 (en) Method of screening for a carnitine transporter agonist or antagonist and its uses
US7229762B2 (en) Proteomic screening for redox state dependent protein—protein interactions
Liang et al. A novel peptide 66CTG stabilizes Myc proto-oncogene protein to promote triple-negative breast cancer growth
TW200405006A (en) Treatment of liver diseases
Zhang et al. Manganese inhibits HBV transcription and promotes HBsAg degradation at non-toxic levels
WO2005049868A1 (en) Methods and agents for screening for compounds capable of modulating her2 expression
US12275759B2 (en) Hepatitis B virus replication inhibitor and pharmaceutical composition for treating hepatitis B comprising the same
Cao Chemical Biology Approaches to Study and Manipulate Translation and Post-Translational Modifications
WO2006070804A1 (en) Method of inhibiting telomerase activity and inhibitor